<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>Patch</title>
    <description>
      <![CDATA[]]>
    </description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>Sava sees positive data on microsensing tech</title>
      <description>
        <![CDATA[Sava Technologies Ltd. reported positive clinical data showing that its multi-molecule biosensor technology can reliably monitor glucose levels beneath the skin in real time. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/728718</guid>
      <pubDate>Tue, 10 Feb 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728718-sava-sees-positive-data-on-microsensing-tech</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2026/Sava-Technologies-multi-molecule-biosensor-technology-2-10.webp?t=1770759368" type="image/jpeg" medium="image" fileSize="842089">
        <media:title type="plain">Sava Technologies' multi-molecule biosensor technology</media:title>
        <media:description type="plain">Sava's multi-molecule biosensor technology. Credit: Sava Technologies Ltd.</media:description>
      </media:content>
    </item>
    <item>
      <title>Vicentra secures additional $13M for Kaleido insulin patch pump</title>
      <description>
        <![CDATA[Investors poured a further $13 million into Vicentra BV for Kaleido, its insulin patch pump system, taking the total raised in the company’s series D financing round to $98 million. The funds come amid significant changes across diabetes technology, particularly the acceleration of patch pumps. Kaleido is one of the smallest, lightest, and most precise insulin patch pumps available.]]>
      </description>
      <guid>http://www.bioworld.com/articles/727605</guid>
      <pubDate>Fri, 09 Jan 2026 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/727605-vicentra-secures-additional-13m-for-kaleido-insulin-patch-pump</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2026/Kaleido-user-9jam26.webp?t=1767995539" type="image/jpeg" medium="image" fileSize="150989">
        <media:title type="plain">Kaleido user</media:title>
        <media:description type="plain">Kaleido insulin patch pump system. Credit: Vincentra</media:description>
      </media:content>
    </item>
    <item>
      <title>Heartbeam wins appeal, gains FDA clearance</title>
      <description>
        <![CDATA[Management is beaming with delight at Heartbeam Inc. as the company's appeal strategy paid off with U.S. FDA clearance for its synthetic 12-lead electrocardiogram software for the assessment of arrhythmias. In November, the Santa Clara, Calif.-based company received a Not Substantially Equivalent determination from the agency on its 510(k) application, which could have substantially delayed commercialization. Following a plan disclosed Nov. 28, the company resolved the agency's issues through an appeal process and active engagement and obtained clearance much more quickly than expected.]]>
      </description>
      <guid>http://www.bioworld.com/articles/726743</guid>
      <pubDate>Wed, 10 Dec 2025 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/726743-heartbeam-wins-appeal-gains-fda-clearance</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2024/Heartbeam-16dec24.webp?t=1734387689" type="image/jpeg" medium="image" fileSize="333840">
        <media:title type="plain">Heartbeam</media:title>
        <media:description type="plain">Heartbeam Inc.’s on-the-go ECG device. Credit: Heartbeam</media:description>
      </media:content>
    </item>
    <item>
      <title>Daewoong’s CLOPAM patch enables injection-free, weekly semaglutide</title>
      <description>
        <![CDATA[Daewoong Pharmaceutical Co. Ltd. and Daewoong Therapeutics Inc. reported that their self-developed microneedle patch loaded with semaglutide demonstrated 80% relative bioavailability compared to an injectable subcutaneous formulation of semaglutide in a pilot human pharmacokinetic study. That far exceeds rates seen in other patches or oral formulations.]]>
      </description>
      <guid>http://www.bioworld.com/articles/723470</guid>
      <pubDate>Tue, 19 Aug 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/723470-daewoongs-clopam-patch-enables-injection-free-weekly-semaglutide</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/Daewoong-13aug25.webp?t=1755121908" type="image/jpeg" medium="image" fileSize="85761">
        <media:title type="plain">Daewoong microneedle patch</media:title>
        <media:description type="plain">A 6.7x magnified view of the microneedle patch developed by Daewoong Therapeutics. Credit: Daewoong Therapeutics</media:description>
      </media:content>
    </item>
    <item>
      <title>Daewoong’s CLOPAM patch enables injection-free, weekly semaglutide</title>
      <description>
        <![CDATA[Daewoong Pharmaceutical Co. Ltd. and Daewoong Therapeutics Inc. reported that their self-developed microneedle patch loaded with semaglutide demonstrated 80% relative bioavailability compared to an injectable subcutaneous formulation of semaglutide in a pilot human pharmacokinetic study. That far exceeds rates seen in other patches or oral formulations.]]>
      </description>
      <guid>http://www.bioworld.com/articles/722848</guid>
      <pubDate>Wed, 13 Aug 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/722848-daewoongs-clopam-patch-enables-injection-free-weekly-semaglutide</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/Daewoong-13aug25.webp?t=1755121908" type="image/jpeg" medium="image" fileSize="85761">
        <media:title type="plain">Daewoong microneedle patch</media:title>
        <media:description type="plain">A 6.7x magnified view of the microneedle patch developed by Daewoong Therapeutics. Credit: Daewoong Therapeutics</media:description>
      </media:content>
    </item>
    <item>
      <title>Bedal raises €10.2M to grow its catheter securement devices</title>
      <description>
        <![CDATA[The €10.2 million (US$11 million) that Bedal International NV recently closed in a funding round is “crucial” for the company’s continued growth and development, co-CEO  Alexander Van Damme, told <em>BioWorld</em>. “The financing provides the necessary resources to scale up operations, enhance product development, and expand market reach, particularly in the competitive U.S. market,” he said.]]>
      </description>
      <guid>http://www.bioworld.com/articles/710297</guid>
      <pubDate>Tue, 16 Jul 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/710297-bedal-raises-102m-to-grow-its-catheter-securement-devices</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2024/Bedal-Flexgrip-device-16july24.webp?t=1721158011" type="image/jpeg" medium="image" fileSize="149758">
        <media:title type="plain">Bedal Flexgrip device</media:title>
        <media:description type="plain">Bedal Flexgrip device</media:description>
      </media:content>
    </item>
    <item>
      <title>My Life Technologies secures $4M for vaccine patch technology </title>
      <description>
        <![CDATA[My Life Technologies Corp. has raised $4 million from investors to fund production and clinical trials for its microneedle technology. Based in Leiden, Netherlands, the company is developing a ceramic patch that can deliver vaccines or drugs through the skin. The technology could prove to be an attractive alternative to standard vaccine injections due to what the company says is its simple and painless delivery.]]>
      </description>
      <guid>http://www.bioworld.com/articles/513385</guid>
      <pubDate>Mon, 15 Nov 2021 13:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/513385-my-life-technologies-secures-4m-for-vaccine-patch-technology</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/financings-international-foreign-currency.webp?t=1751908080" type="image/png" medium="image" fileSize="509882">
        <media:title type="plain">International currency symbols</media:title>
      </media:content>
    </item>
    <item>
      <title>Grapheal developing intelligent patch to remotely monitor healing of chronic wounds</title>
      <description>
        <![CDATA[PARIS &ndash; Grapheal SAS, of Grenoble, France, is developing a new generation of dressings integrating an embedded electronic biosensor. The Grapheal device consists of monolayer graphene on a polymer layer 0.3 nanometers thick. &ldquo;This noninvasive embedded device collects data from the wound. The wireless e-health wound monitoring system, or smart patch, remotely reports the status of chronic wounds to the care team,&rdquo; Vincent Bouchiat, co-founder and CEO at Grapheal, told <em>BioWorld MedTech.</em>]]>
      </description>
      <guid>http://www.bioworld.com/articles/431736</guid>
      <pubDate>Wed, 11 Dec 2019 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/431736-grapheal-developing-intelligent-patch-to-remotely-monitor-healing-of-chronic-wounds</link>
    </item>
    <item>
      <title>GC Pharma, Vaxess partner on global commercialization of flu vaccine patch</title>
      <description>
        <![CDATA[HONG KONG – South Korea's major pharmaceutical company <a href="https://www.cortellis.com/intelligence/qsearch/&quot;GC Pharma&quot;" target="_blank">GC Pharma Corp.</a>, based in Yong-in, Gyeonggi-do, and the Cambridge, Mass.-based U.S. biotech <a href="https://www.cortellis.com/intelligence/qsearch/Vaxess Technologies&quot;" target="_blank">Vaxess Technologies Inc.</a>, have partnered to globally commercialize a flu vaccine patch based on Vaxess' Mimix Smart Release Patch technology. The patch is designed to deliver medicines and vaccines through silk microneedles that dissolve at a precise rate.]]>
      </description>
      <guid>http://www.bioworld.com/articles/430664</guid>
      <pubDate>Fri, 25 Oct 2019 00:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/430664-gc-pharma-vaxess-partner-on-global-commercialization-of-flu-vaccine-patch</link>
    </item>
    <item>
      <title>Irhythm, Verily partner to develop screening approach for asymptomatic AF</title>
      <description>
        <![CDATA[]]>
      </description>
      <guid>http://www.bioworld.com/articles/430242</guid>
      <pubDate>Tue, 10 Sep 2019 00:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/430242-irhythm-verily-partner-to-develop-screening-approach-for-asymptomatic-af</link>
    </item>
    <item>
      <title>FDA gives nod to Theranica's wearable for the acute treatment of migraine pain</title>
      <description>
        <![CDATA[Netanya, Israel-based Theranica Bioelectronics Ltd., which is focusing on the development of advanced electroceuticals for migraine and other pain disorders, scored a win at the U.S. FDA, with the agency granting its de novo request for the smartphone-controlled Nerivio Migra.]]>
      </description>
      <guid>http://www.bioworld.com/articles/421303</guid>
      <pubDate>Thu, 30 May 2019 00:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/421303-fda-gives-nod-to-theranica-s-wearable-for-the-acute-treatment-of-migraine-pain</link>
    </item>
  </channel>
</rss>
